Investor Alert

Market Pulse Archives

Oct. 23, 2020, 6:21 a.m. EDT

Coronavirus tally: Global cases of COVID-19 41.8 million, 1.14 million deaths and FDA approves remdesivir as treatment

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Gilead Sciences Inc. (GILD)

or Cancel Already have a watchlist? Log In

By Ciara Linnane


The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed to 41.8 million on Friday, according to data aggregated by Johns Hopkins University , while the death toll rose to 1.14 million. The U.S. has the highest case total at 8.4 million and deaths at 223,051. There was good news on the medical front, when the U.S. Food and Drug Administration gave a full approval for Gilead Sciences Inc.'s /zigman2/quotes/210293917/composite GILD +0.89% remdesivir as a treatment for patients who have been hospitalized with COVID-19 infections. The antiviral drug, which has the official name Veklury, in early May received an emergency use authorization, which is a less rigorous type of regulatory authorization used during public-health emergencies. Veklury is the first COVID-19 therapy to receive a full FDA approval during the pandemic and has been considered the standard of care when it comes to treating hospitalized patients since it received emergency authorization. Brazil has the second highest death toll at 155,900 and is third by cases at 5.3 million. India is second in cases with 7.8 million, and third in deaths at 117,306. Mexico has the fourth highest death toll at 87,415 and tenth highest case tally at 874,171. The U.K has 44,437 deaths, the highest in Europe and fifth highest in the world, and 813,451 cases.

US : U.S.: Nasdaq
$ 60.03
+0.53 +0.89%
Volume: 5.04M
Nov. 27, 2020 1:00p
P/E Ratio
Dividend Yield
Market Cap
$74.58 billion
Rev. per Employee

Get news alerts on Gilead Sciences Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.